Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Vivian Wei
Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-Pd-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Efficacy of Chemotherapy or Chemo-Anti-Pd-1 Combination After Failed Anti-Pd-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Series From Lysa Centers
American Journal of Hematology
Hematology
Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group
Klinicka Onkologie
Oncology
Evita: Phase I/Ii Study of Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
New England Journal of Medicine
Medicine
Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia
OncoTargets and Therapy
Oncology
Pharmacology
Mocetinostat for Relapsed Classical Hodgkin's Lymphoma: An Open-Label, Single-Arm, Phase 2 Trial
The Lancet Oncology
Oncology
Sintilimab for Relapsed/Refractory (R/R) Extranodal Nk/T Cell Lymphoma (Enktl): A Multicenter, Single-Arm, Phase 2 Trial (Orient-4)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology